Adagrasib

Products

We are here to help in anything you need. Please use our online system or send an email to inquiry@alfa-chemistry.com.

Adagrasib

Inquiry

Catalog Number	PR2326521713
CAS	2326521-71-3
Description	Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Synonyms	MRTX-849
IUPAC Name	2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
Molecular Weight	604.12
Molecular Formula	C32H35ClFN7O2
InChI	InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1
InChI Key	PEMUGDMSUDYLHU-ZEQRLZLVSA-N
EC Number	870-640-0
Isomeric SMILES	CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F
Therapeutic Category	Oncology

It should be noted that our service is only used for research, not for clinical use.

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies